SHLD2 and neoplasm: Dosing of rats bearing established MDA-MB-436 BRCA1/SHLD2 defective tumours with ART812 resulted in significant tumour inhibition (Fig. 3j, k) and was well-tolerated (Supplementary Fig. 3h).